Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma

Running, not enrolling · Not applicable

Conditions studied: Chronic Subdural Hematoma

In brief

This international multicenter study evaluates the efficacy and safety of middle meningeal artery embolization (MMAE) using PVA particles or liquid embolic agents as a perioperative treatment to prevent the recurrence of chronic subdural hematoma (cSDH). All participating patients across centers in the Czech Republic and Slovakia will receive the minimally invasive MMAE procedure within 7 days prior to or after surgical evacuation, with the primary goal of assessing hematoma recurrence rates and procedure-related complications over a 90-day follow-up period.

Key facts

Study ID

NCT07751887

Run by

University Hospital Hradec Kralove

People needed

200

Starts

2026-06-01

Expected to finish

2029-06-01

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older.
• Diagnosis of a symptomatic or asymptomatic chronic or subacute subdural hematoma (cSDH) confirmed by neuroimaging (CT or MRI).
• Hematoma thickness of 5 mm or greater at its widest point on baseline neuroimaging.
• Patient is managed either conservatively or via standard surgical evacuation (e.g., burr-hole craniostomy) where MMAE is planned as a standalone or adjunctive treatment.
• Written informed consent provided by the patient or a legally authorized representative.

You may not qualify if…

• Acute subdural hematoma requiring emergency surgical decompression due to severe neurological deficit with signs of impending herniation.
• Evidence of an active intracranial infection or sepsis.
• Known vascular malformation, aneurysm, or dural arteriovenous fistula as the source of the hematoma.
• Severe uncorrectable coagulopathy or bleeding disorder (e.g., platelet count <50,000/µL or INR >2.0 that cannot be safely corrected before the procedure).
• Severe renal impairment (e.g., eGFR <30 mL/min/1.73m²) or known severe allergy to iodinated contrast media (unless adequate premedication is possible).
• Life expectancy of less than 3 months due to severe comorbid conditions.

Where it is running

• University Hospital Hradec Kralove — Hradec Králové, Czechia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.